Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Keros Therapeutics Inc (KROS)

Keros Therapeutics Inc (KROS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 689,834
  • Shares Outstanding, K 40,507
  • Annual Sales, $ 150 K
  • Annual Income, $ -152,990 K
  • EBIT $ -204 M
  • EBITDA $ -203 M
  • 60-Month Beta 1.20
  • Price/Sales 4,538.93
  • Price/Cash Flow N/A
  • Price/Book 1.19

Options Overview Details

View History
  • Implied Volatility 91.52% ( -1.81%)
  • Historical Volatility 379.46%
  • IV Percentile 89%
  • IV Rank 40.72%
  • IV High 146.43% on 12/12/24
  • IV Low 53.79% on 08/26/24
  • Put/Call Vol Ratio 0.23
  • Today's Volume 1,463
  • Volume Avg (30-Day) 1,367
  • Put/Call OI Ratio 0.81
  • Today's Open Interest 15,546
  • Open Int (30-Day) 6,929

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 15 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.94
  • Number of Estimates 10
  • High Estimate 3.15
  • Low Estimate -1.63
  • Prior Year -1.34
  • Growth Rate Est. (year over year) +29.85%

Price Performance

See More
Period Period Low Period High Performance
1-Month
15.67 +8.68%
on 12/12/24
72.37 -76.47%
on 12/09/24
-37.11 (-68.54%)
since 11/20/24
3-Month
15.67 +8.68%
on 12/12/24
72.37 -76.47%
on 12/09/24
-38.77 (-69.48%)
since 09/20/24
52-Week
15.67 +8.68%
on 12/12/24
73.00 -76.67%
on 02/29/24
-16.75 (-49.59%)
since 12/20/23

Most Recent Stories

More News
Stocks Settle Lower as Bond Yields Climb

The S&P 500 Index ($SPX ) (SPY ) Thursday closed down -0.54%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed down -0.53%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down -0.68%. Stock indexes...

AMAT : 163.59 (+1.33%)
CVS : 44.36 (+1.32%)
AVGO : 220.79 (+1.13%)
$IUXX : 21,289.15 (+0.85%)
UNH : 500.13 (+2.22%)
ZNH25 : 108-310s (+0.33%)
QCOM : 152.89 (+1.66%)
JAZZ : 122.97 (+0.10%)
KDP : 32.37 (-0.09%)
LRCX : 71.79 (+0.81%)
WBD : 10.69 (+1.91%)
$DOWI : 42,840.26 (+1.18%)
Keros Therapeutics Announces Voluntary Halt of Dosing in TROPOS Trial Due to Safety Review Findings

Keros Therapeutics halts certain dosing in TROPOS trial due to safety concerns while continuing to collect safety and efficacy data.Quiver AI SummaryKeros Therapeutics, Inc. has announced the voluntary...

KROS : 17.03 (+0.65%)
Stocks Pressured by Higher Bond Yields

The S&P 500 Index ($SPX ) (SPY ) today is down -0.18%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -0.16%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.41%. Stock indexes today are posting...

AMAT : 163.59 (+1.33%)
AVGO : 220.79 (+1.13%)
$IUXX : 21,289.15 (+0.85%)
ZNH25 : 108-310s (+0.33%)
QCOM : 152.89 (+1.66%)
JAZZ : 122.97 (+0.10%)
EFX : 258.43 (+1.88%)
KDP : 32.37 (-0.09%)
LRCX : 71.79 (+0.81%)
WBD : 10.69 (+1.91%)
$DOWI : 42,840.26 (+1.18%)
CACI : 402.72 (+0.70%)
Keros Stock Hits Rock Bottom After Pulmonary Hypertension Trial Halt, But Retail Bets On A Rebound

Optimistic retail users highlighted Keros’ broader pipeline, including its potential in obesity treatments and other promising partnerships.

KROS : 17.03 (+0.65%)
Stocks Weaken on Stagflation Concerns

The S&P 500 Index ($SPX ) (SPY ) today is down -0.28%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -0.04%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.58%. Stock indexes today are mildly...

AMAT : 163.59 (+1.33%)
AVGO : 220.79 (+1.13%)
$IUXX : 21,289.15 (+0.85%)
ZNH25 : 108-310s (+0.33%)
QCOM : 152.89 (+1.66%)
JAZZ : 122.97 (+0.10%)
EFX : 258.43 (+1.88%)
KDP : 32.37 (-0.09%)
LRCX : 71.79 (+0.81%)
WBD : 10.69 (+1.91%)
$DOWI : 42,840.26 (+1.18%)
CACI : 402.72 (+0.70%)
Keros Therapeutics Announces Update on the Phase 2 TROPOS Trial

KROS : 17.03 (+0.65%)
Keros Therapeutics Reports Positive Phase 2 Data for Elritercept in Lower-Risk Myelodysplastic Syndromes and Myelofibrosis at ASH 2024

Elritercept shows promise for treating lower-risk myelodysplastic syndromes and myelofibrosis, demonstrating durable transfusion independence and improving patient-reported outcomes.Quiver AI SummaryKeros...

KROS : 17.03 (+0.65%)
Keros Therapeutics Presents Clinical Data from its Elritercept Program at the 66th American Society of Hematology Annual Meeting and Exposition

KROS : 17.03 (+0.65%)
Keros Therapeutics Announces Global License Agreement with Takeda to Advance Elritercept

KROS : 17.03 (+0.65%)
Keros Therapeutics Announces Participation at Upcoming Healthcare Conferences

KROS : 17.03 (+0.65%)

Business Summary

Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of novel treatments for hematological and musculoskeletal disorders. The company's product pipeline consists of KER-050, KER-047and KER-012 which are in clinical stage....

See More

Key Turning Points

3rd Resistance Point 18.59
2nd Resistance Point 18.11
1st Resistance Point 17.57
Last Price 17.03
1st Support Level 16.55
2nd Support Level 16.08
3rd Support Level 15.54

See More

52-Week High 73.00
Fibonacci 61.8% 51.10
Fibonacci 50% 44.33
Fibonacci 38.2% 37.57
Last Price 17.03
52-Week Low 15.67

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar